Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 34Carcinoma, Non-Small-Cell Lung 20Squamous Cell Carcinoma of Head and Neck 19Esophageal Neoplasms 19Head and Neck Neoplasms 13Nasopharyngeal Carcinoma 12Uterine Cervical Neoplasms 11Pancreatic Neoplasms 9Oropharyngeal Neoplasms 8Lung Neoplasms 7Glioblastoma 6Esophageal Squamous Cell Carcinoma 6Carcinoma, Squamous Cell 6Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Mouth Neoplasms 4Hypopharyngeal Neoplasms 4Colorectal Neoplasms 4Carcinoma 4Adenocarcinoma 4Radiation Injuries 3Pathologic Complete Response 3Laryngeal Neoplasms 3Breast Neoplasms 3Thymoma 2Resectable Esophageal Cancer 2Neoplasms by Site 2Nasopharyngeal Neoplasms 2NSCLC 2

Interventions

Chemoradiotherapy 2Radiation 1Paclitaxel 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Cetuximab 1Carboplatin 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Resectable Esophageal Cancer × Chemoradiotherapy × Clear all
NCT07385664 2026-02-04

FAIR

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
66 enrolled
Gastrointestinal

Resectable Esophageal Cancer

NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡